MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schetz, J. A.
Right arrow Articles by Sibley, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schetz, J. A.
Right arrow Articles by Sibley, D. R.

Vol. 57, Issue 1, 144-152, January 2000

Nonconserved Residues in the Second Transmembrane-Spanning Domain of the D4 Dopamine Receptor Are Molecular Determinants of D4-Selective Pharmacology

John A. Schetz, Peter S. Benjamin, and David R. Sibley

Molecular Neuropharmacology Section, Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland

The molecular determinants that govern selective ligand binding to the rat D4 dopamine receptor were investigated by substituting D2 dopamine receptor sequences into a D4 dopamine receptor background. The resulting mutant D4 dopamine receptors were then screened with a panel of 10 selective and nonselective ligands, which included two allosteric modulators as sensitive measures of protein conformational changes. Mutation of a phenylalanine at position 88 in the second transmembrane-spanning domain (TMS2) of the D4 receptor to the corresponding valine in the D2 receptor D4-F88V resulted in an ~100-fold decrease in the affinity of the highly D4-selective drug 3-{[4-(4-iodophenyl) piperazin-1-yl]methyl}-1H-pyrrolo[2,3-b]pyridine (L-750,667) without substantially affecting the binding of the other ligands. Mutations at the extracellular side of D4-TMS3 produced moderate decreases in L-750,667 binding affinities with concomitant increases in binding affinity for the D2/D3-selective antagonist (-)-raclopride. However, the binding affinities of these same D4-TMS3 mutants for the allosteric modulator isomethylbutylamiloride also were an anomalous 6- to 20-fold higher than either wild-type receptor. In the combined D4-F88V/TMS3 mutants, L-750,667 binding affinity was further decreased, but this decrease was not additive. More importantly, the combined D4-F88V/TMS3 mutants had (-)-raclopride and isomethylbutylamiloride binding properties that reverted back to those of the wild-type D4-receptor. In contrast to the D4-F88V mutant, the adjacent D4-L87W mutant had an increased affinity for ligands with extended structures, but had essentially no effect on ligands with compact structures. These findings demonstrate that two residues near the extracellular side of D4-TMS2 are critical molecular determinants for the selective binding of L-750,667 and ligands with extended structures.


Copyright © 2000 by U.S. Government



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
G. Lebon, C. J. Langmead, B. G. Tehan, and E. C. Hulme
Mutagenic Mapping Suggests a Novel Binding Mode for Selective Agonists of M1 Muscarinic Acetylcholine Receptors
Mol. Pharmacol., February 1, 2009; 75(2): 331 - 341.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. S. Ericksen, D. F. Cummings, H. Weinstein, and J. A. Schetz
Ligand Selectivity of D2 Dopamine Receptors Is Modulated by Changes in Local Dynamics Produced by Sodium Binding
J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 40 - 54.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. A. Al-Fulaij, Y. Ren, M. Beinborn, and A. S. Kopin
Identification of Amino Acid Determinants of Dopamine 2 Receptor Synthetic Agonist Function
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 298 - 307.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Kortagere, P. Gmeiner, H. Weinstein, and J. A. Schetz
Certain 1,4-Disubstituted Aromatic Piperidines and Piperazines with Extreme Selectivity for the Dopamine D4 Receptor Interact with a Common Receptor Microdomain
Mol. Pharmacol., December 1, 2004; 66(6): 1491 - 1499.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
T. R. Hollon, M. J. Bek, J. E. Lachowicz, M. A. Ariano, E. Mezey, R. Ramachandran, S. R. Wersinger, P. Soares-da-Silva, Z. F. Liu, A. Grinberg, et al.
Mice Lacking D5 Dopamine Receptors Have Increased Sympathetic Tone and Are Hypertensive
J. Neurosci., December 15, 2002; 22(24): 10801 - 10810.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics